Platelet-rich plasma concentrations regulate MSCs osteogenesis via MAPK/PI3K-AKT pathways to mitigate inflammatory...

Area of Science:

• Orthopedics and Regenerative Medicine
• Cell Biology and Molecular Mechanisms

Background:

• Bone homeostasis relies on osteoblasts and osteoclasts; impaired osteoblast function is linked to bone diseases.
• Current treatments for bone loss are limited, necessitating novel bone formation strategies.
• Platelet-rich plasma (PRP), a source of growth factors, is used in regenerative medicine, but its role in inflammatory bone destruction is unclear.

Purpose of the Study:

• To investigate the effects of PRP on mesenchymal stem cell (MSC) viability, proliferation, differentiation, and cell death.
• To evaluate the therapeutic efficacy of different PRP concentrations (1% and 3%) on LPS-induced inflammatory bone destruction in vivo.

Main Methods:

• In vitro analysis of PRP effects on MSCs (viability, cell death, proliferation, differentiation) at 1% and 3% concentrations.
• In vivo study using LPS-induced inflammatory bone destruction model to assess PRP's therapeutic effects.

Main Results:

• PRP enhanced MSC activity and promoted osteogenesis.
• 3% PRP reduced cell death and increased proliferation in LPS-treated MSCs via the PI3K/AKT pathway.
• 1% PRP promoted MSC differentiation into osteoblasts via the MAPK pathway.
• PRP demonstrated a protective effect against LPS-induced bone loss by enhancing bone formation in vivo.

Conclusions:

• PRP effectively promotes MSC activity and osteogenesis.
• Distinct PRP concentrations exert differential effects on MSCs, influencing cell survival, proliferation, and differentiation through specific signaling pathways (PI3K/AKT and MAPK).
• PRP shows therapeutic potential in ameliorating inflammatory bone loss via concentration-dependent mechanisms.